8. Как не умереть от болезней печени

‹‹1››. Chiras, DD. Human Biology. Burlington, MA: Jones & Bartlett Learning; 2015.

‹‹2››. Centers for Disease Control and Prevention. Deaths: final data for 2013 table 10. Number of deaths from 113 selected causes. National Vital Statistics Report 2016;64(2).

‹‹3››. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER stat factsheets: liver and intrahepatic bile duct cancer. http://seer.cancer.gov/statfacts/html/livibd.html. Accessed May 3, 2015.

‹‹4››. Holubek WJ, Kalman S, Hoffman RS. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2006;43(4):880.

‹‹5››. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–45.

‹‹6››. CDC Morbidity and Mortality Weekly Report. Alcohol-attributable deaths and years of potential life l— United States, 2001. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5337a2.htm. September 24, 2004. Accessed March 2, 2015.

‹‹7››. Centers for Disease Control and Prevention. Fact sheets-alcohol use and your health. http://www.cdc. gov/alcohol/fact-sheets/alcohol-use.htm. November 7, 2014. Accessed March 2, 2015.

‹‹8››. Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis. 2012;16(4):659–66.

‹‹9››. Lane BP, Lieber CS. Ultrastructural alterations in human hepatocytes following ingestion of ethanol with adequate diets. Am J Pathol. 1966;49(4):593–603.

‹‹10››. Mendenhall CL. Anabolic steroid therapy as an adjunct to diet in alcoholic hepatic steatosis. Am J Dig Dis. 1968;13(9):783–91.

‹‹11››. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51(1): 307–28.

‹‹12››. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis. 2004;24(3):217–32.

‹‹13››. Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology. 1972;63(6):1026–35.

‹‹14››. Woerle S, Roeber J, Landen MG. Prevalence of alcohol dependence among excessive drinkers in New Mexico. Alcohol Clin Exp Res. 2007;31(2):293–8.

‹‹15››. Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. J Addict Dis. 2009; 28(2):145–57.

‹‹16››. Gr?nbaek M. The positive and negative health effects of alcohol and the public health implications. J Intern Med. 2009;265(4):407–20.

‹‹17››. Britton A, Marmot MG, Shipley M. Who benefits most from the cardioprotective properties of alcohol consumption— health freaks or couch potatoes? J Epidemiol Community Health. 2008;62(10):905–8.

‹‹18››. Agarwal DP. Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms. Alcohol Alcohol. 2002;37(5):409–15.

‹‹19››. Britton A, Marmot MG, Shipley M. Who benefits most from the cardioprotective properties of alcohol consumption— health freaks or couch potatoes? J Epidemiol Community Health. 2008; 62(10):905–8.

‹‹20››. Britton A, Marmot MG, Shipley M. Who benefits most from the cardioprotective properties of alcohol consumption— health freaks or couch potatoes? J Epidemiol Community Health. 2008;62(10):905–8.

‹‹21››. Kechagias S, Ernersson ?, Dahlqvist O, et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut. 2008;57(5):649–54.

‹‹22››. McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic fatty liver disease. J Acad Nutr Diet. 2012;112(3):401–9.

‹‹23››. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol Annu. 1989;24:275–302.

‹‹24››. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014;S1542–3565(14):00602–8.

‹‹25››. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007; 47(5):711–7.

‹‹26››. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007; 47(5):711–7.

‹‹27››. Longato L. Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair. 2013;6(1):14.

‹‹28››. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37(4):909–16.

‹‹29››. Kontogianni MD, Tileli N, Margariti A, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014;33(4):678–83.

‹‹30››. Kim EJ, Kim BH, Seo HS, et al. Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PLoS ONE. 2014;9(6):e97841.

‹‹31››. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non- alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol. 2009;44(4):471–7.

‹‹32››. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature. 2010;464(7293): 1357–61.

‹‹33››. Ioannou GN, Haigh WG, Thorning D, Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res. 2013;54(5):1326–34.

‹‹34››. U.S. Department of Agriculture Agricultural Research Ser vice. National Nutrient Database for Standard Reference Release 27. Basic Report: 21359, McDonald’s, sausage McMuffi n with egg. http://ndb.nal. usda.gov/ndb/foods/show/6845. Accessed March 2, 2015.

‹‹35››. Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology. 2009;50(1):175–84.

‹‹36››. National Institute of Diabetes and Digestive and Kidney Diseases. Liver transplantation. http://www. niddk.nih.gov/health-information/health-topics/liver-disease/liver-transplant/Pages/facts.aspx. June 2010. Accessed March 2, 2015.

‹‹37››. Kwak JH, Baek SH, Woo Y, et al. Beneficial immunostimulatory effect of short-term Chlorella supplementation: enhancement of natural killer cell activity and early inflammatory response (randomized, double-blinded, placebo-controlled trial). Nutr J. 2012;11:53.

‹‹38››. Azocar J, Diaz A. Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World J Gastroenterol. 2013 Feb 21;19(7):1085–90.

‹‹39››. Goozner M. Why Sovaldi shouldn’t cost $84,000. Mod Healthc. 2014;44(18):26.

‹‹40››. Lock G, Dirscherl M, Obermeier F, et al. Hepatitis C-contamination of toothbrushes: myth or reality? J Viral Hepat. 2006;13(9):571–3.

‹‹41››. Bocket L, Chevaliez S, Talbodec N, Sobaszek A, Pawlotsky JM, Yazdanpanah Y. Occupational transmission of hepatitis C virus resulting from use of the same supermarket meat slicer. Clin Microbiol Infect. 2011;17(2):238–41.

‹‹42››. Teo CG. Much meat, much malady: changing perceptions of the epidemiology of hepatitis E. Clin Microbiol Infect. 2010;16(1):24–32.

‹‹43››. Yazaki Y, Mizuo H, Takahashi M, et al. Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J Gen Virol. 2003;84(Pt 9):2351–7.

‹‹44››. Feagins AR, Opriessnig T, Guenette DK, Halbur PG, Meng XJ. Detection and characterization of infectious Hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J Gen Virol. 2007;88(Pt 3):912–7.

‹‹45››. Feagins AR, Opriessnig T, Guenette DK, Halbur PG, Meng XJ. Detection and characterization of infectious Hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J Gen Virol. 2007;88(Pt 3):912–7.

‹‹46››. Dalton HR, Bendall RP, Pritchard C, Henley W, Melzer D. National mortality rates from chronic liver disease and consumption of alcohol and pig meat. Epidemiol Infect. 2010; 138(2): 174–82.

‹‹47››. Emerson SU, Arankalle VA, Purcell RH. Thermal stability of hepatitis E virus. J Infect Dis. 2005 Sep 1;192(5):930–3.

‹‹48››. Centers for Disease Control and Prevention. What can you do to protect yourself and your family from food poisoning? http://www.cdc.gov/foodsafety/prevention.html. September 6, 2013. Accessed March 11, 2015.

‹‹49››. Shinde NR, Patil TB, Deshpande AS, Gulhane RV, Patil MB, Bansod YV. Clinical profile, maternal and fetal outcomes of acute hepatitis E in pregnancy. Ann Med Health Sci Res. 2014; 4(Suppl 2):S133–9.

‹‹50››. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399–408.

‹‹51››. Yu EL, Sivagnanam M, Ellis L, Huang JS. Acute hepatotoxicity after ingestion of Morinda citrifolia (Noni Berry) juice in a 14-year-old boy. J Pediatr Gastroenterol Nutr. 2011;52(2):222–4.

‹‹52››. Licata A, Craxt A. Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity: a rebuttal. Intern Emerg Med. 2014;9(5):601–2.

‹‹53››. Lobb AL. Science in liquid dietary supplement promotion: the misleading case of mangosteen juice. Hawaii J Med Public Health. 2012;71(2):46–8.

‹‹54››. Lobb AL. Science in liquid dietary supplement promotion: the misleading case of mangosteen juice. Hawaii J Med Public Health. 2012;71(2):46–8.

‹‹55››. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord. 2001;25(3):316–24.

‹‹56››. US Government Accountability Offi ce. Dietary Supplements Containing Ephedra: Health Risks and FDA’s Oversight. http://www.gao.gov/assets/120/110228.pdf. July 23, 2003. Accessed March 2, 2015.

‹‹57››. Preuss HG, Bagchi D, Bagchi M, Rao CV, Dey DK, Satyanarayana S. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab. 2004;6(3):171–80.

‹‹58››. Fong TL, Klontz KC, Canas-Coto A, et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol. 2010;105(7):1561–6.

‹‹59››. Ye EQ, Chacko SA, Chou EL, Kugizaki M, Liu S. Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. J Nutr. 2012;142(7): 1304–13.

‹‹60››. Karl JP, Saltzman E. The role of whole grains in body weight regulation. Adv Nutr. 2012; 3(5):697–707.

‹‹61››. Ye EQ, Chacko SA, Chou EL, Kugizaki M, Liu S. Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. J Nutr. 2012;142(7): 1304–13.

‹‹62››. Chang H-C, Huang C-N, Yeh D-M, Wang S-J, Peng C-H, Wang C-J. Oat prevents obesity and abdominal fat distribution, and improves liver function in humans. Plant Foods Hum Nutr. 2013;68(1):18–23.

‹‹63››. Chang H-C, Huang C-N, Yeh D-M, Wang S-J, Peng C-H, Wang C-J. Oat prevents obesity and abdominal fat distribution, and improves liver function in humans. Plant Foods Hum Nutr. 2013;68(1):18–23.

‹‹64››. Georgoulis M, Kontogianni MD, Tileli N, et al. The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. Eur J Nutr. 2014;53(8):1727–35.

‹‹65››. Valenti L, Riso P, Mazzocchi A, Porrini M, Fargion S, Agostoni C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2013;2013:145421.

‹‹66››. Suda I, Ishikawa F, Hatakeyama M, et al. Intake of purple sweet potato beverage affects on serum hepatic biomarker levels of healthy adult men with borderline hepatitis. Eur J Clin Nutr. 2008;62(1):60–7.

‹‹67››. Sun J, Chu YF, Wu X, Liu RH. Antioxidant and antiproliferative activities of common fruits. J Agric Food Chem. 2002;50(25):7449–54.

‹‹68››. Ferguson PJ, Kurowska EM, Freeman DJ, Chambers AF, Koropatnick J. In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. Nutr Cancer. 2006;56(1):86–94.

‹‹69››. Sun J, Hai Liu R. Cranberry phytochemical extracts induce cell cycle arrest and apoptosis in human MCF-7 breast cancer cells. Cancer Lett. 2006;241(1):124–34.

‹‹70››. Ferguson PJ, Kurowska EM, Freeman DJ, Chambers AF, Koropatnick J. In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. Nutr Cancer. 2006; 56(1):86–94.

‹‹71››. Kresty LA, Howell AB, Baird M. Cranberry proanthocyanidins mediate growth arrest of lung cancer cells through modulation of gene expression and rapid induction of apoptosis. Molecules. 2011;16(3):2375–90.

‹‹72››. Seeram NP, Adams LS, Zhang Y, et al. Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J Agric Food Chem. 2006;54(25):9329–39.

‹‹73››. Kim KK, Singh AP, Singh RK, et al. Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. Int J Oncol. 2012;40(1):227–35.

‹‹74››. Deziel B, MacPhee J, Patel K, et al. American cranberry (Vaccinium macrocarpon) extract affects human prostate cancer cell growth via cell cycle arrest by modulating expression of cell cycle regulators. Food Funct. 2012;3(5):556–64.

‹‹75››. Liu M, Lin LQ, Song BB, et al. Cranberry phytochemical extract inhibits SGC-7901 cell growth and human tumor xenografts in Balb/c nu/nu mice. J Agric Food Chem. 2009;57(2):762–8.

‹‹76››. Seeram NP, Adams LS, Hardy ML, Heber D. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem. 2004;52(9):2512–7.

‹‹77››. Grace MH, Massey AR, Mbeunkui F, Yousef GG, Lila MA. Comparison of health-relevant flavonoids in commonly consumed cranberry products. J Food Sci. 2012;77(8):H176–83.

‹‹78››. Grace MH, Massey AR, Mbeunkui F, Yousef GG, Lila MA. Comparison of health-relevant flavonoids in commonly consumed cranberry products. J Food Sci. 2012;77(8):H176–83.

‹‹79››. Vinson JA, Bose P, Proch J, Al Kharrat H, Samman N. Cranberries and cranberry products: powerful in vitro, ex vivo, and in vivo sources of antioxidants. J Agric Food Chem. 2008; 56(14):5884–91.

‹‹80››. White BL, Howard LR, Prior RL. Impact of different stages of juice processing on the anthocyanin, flavonol, and procyanidin contents of cranberries. J Agric Food Chem. 2011;59(9):4692–8.

‹‹81››. Arnesen E, Huseby N-E, Brenn T, Try K. The Tromse heart study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest. 1986;46(1):63–70.

‹‹82››. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology. 2005;129(6):1928–36.

‹‹83››. Salgia R, Singal AG. Hepatocellular carcinoma and other liver lesions. Med Clin North Am. 2014; 98(1):103–18.

‹‹84››. Sang LX, Chang B, Li X-H, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol. 2013;13:34.

‹‹85››. Lai GY, Weinstein SJ, Albanes D, et al. The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer. 2013;109(5):1344–51.

‹‹86››. Fujita Y, Shibata A, Ogimoto I, et al. The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br J Cancer. 2006;94(5):737–9.

‹‹87››. Danielsson J, Kangastupa P, Laatikainen T, Aalto M, Niemel? O. Dose-and gender-dependent interactions between coffee consumption and serum GGT activity in alcohol consumers. Alcohol Alcohol. 2013;48(3):303–7.

‹‹88››. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1413–21.e1.

‹‹89››. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95.

‹‹90››. Cardin R, Piciocchi M, Martines D, Scribano L, Petracco M, Farinati F. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 2013;45(6): 499–504.

‹‹91››. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology. 2013;144(4):670–2.

‹‹92››. Ng V, Saab S. Can daily coffee consumption reduce liver disease-related mortality? Clin Gastroenterol Hepatol. 2013;11(11):1422–3.

‹‹93››. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology. 2013;144(4):670–2.

‹‹94››. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl). 2004; 176(1):1–29.

‹‹95››. O’Keefe JH, Bhatti SK, Patil HR, DiNicolantonio JJ, Lucan SC, Lavie CJ. Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. J Am Coll Cardiol. 2013;62(12):1043–51.

Похожие книги из библиотеки